- Trials with a EudraCT protocol (9)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
9 result(s) found for: HPV-positive oropharyngeal cancer.
Displaying page 1 of 1.
EudraCT Number: 2014-003392-32 | Sponsor Protocol Number: 2014/VCC/0014 | Start Date*: 2014-10-24 | |||||||||||
Sponsor Name:Velindre NHS Trust | |||||||||||||
Full Title: A Phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV)-positive oropharyngeal cancer | |||||||||||||
Medical condition: Oropharyngeal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Trial now transitioned) ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-013438-26 | Sponsor Protocol Number: 135 | Start Date*: 2010-08-24 |
Sponsor Name:Karolinska University Hospital | ||
Full Title: A multicentre, open label, randomised phase II study with docetaxel (Taxotere®), cisplatin and 5-fluorouracil as induction chemotherapy, combined with hyperfractionated radiotherapy and cetuximab ... | ||
Medical condition: Patients with non-resectable stage III-IV head and neck cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-001456-21 | Sponsor Protocol Number: B9991016 | Start Date*: 2017-05-09 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY (CISPLATIN PLUS DEFINITIVE RADIATION THERAPY) VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN... | |||||||||||||
Medical condition: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Prematurely Ended) DE (Prematurely Ended) PL (Completed) AT (Prematurely Ended) ES (Prematurely Ended) IE (Completed) PT (Prematurely Ended) HU (Prematurely Ended) FR (Completed) GR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004349-29 | Sponsor Protocol Number: 01-10-2014 | Start Date*: 2015-04-01 | ||||||||||||||||
Sponsor Name:Rigshospitalet | ||||||||||||||||||
Full Title: Mesenchymal stem cells for radiation-induced xerostomia (MESRIX) in previous HPV-positive oropharyngeal head and neck cancer patients | ||||||||||||||||||
Medical condition: The study will include participants with xerostomi (International Classification of Diseases-10: DQ 838A) and oropharyngeal cancer (DC 10). | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-000308-13 | Sponsor Protocol Number: 1740-HNCG | Start Date*: 2019-08-30 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC) | |||||||||||||
Full Title: Randomized Phase II study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab versus Durvalumab plus Radiotherapy followed by Adjuvant Tremelimumab an... | |||||||||||||
Medical condition: Oropharyngeal Squamous Cell Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004161-68 | Sponsor Protocol Number: AG013-ODOM-201 | Start Date*: 2018-10-31 | |||||||||||
Sponsor Name:Oragenics, Inc. | |||||||||||||
Full Title: A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically-applied AG013 for the attenuation of oral mucositis in subjects with cance... | |||||||||||||
Medical condition: Oral mucositis (OM) induced by chemoradiation therapy (CRT) used for the treatment of head and neck cancers (HNC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000626-60 | Sponsor Protocol Number: UC-0130/1804 | Start Date*: 2019-01-08 |
Sponsor Name:UNICANCER | ||
Full Title: A multicenter, randomized, open label, phase II study evaluating the feasibility and tolerance of nivolumab neoadjuvant immunotherapy in high risk HPV driven Oropharynx Cancer. | ||
Medical condition: High risk Human Papilloma Virus (HPV)-driven oropharynx cancer patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003302-40 | Sponsor Protocol Number: WO40242 | Start Date*: 2018-04-10 | |||||||||||
Sponsor Name:F. Hoffman-La Roche Ltd. | |||||||||||||
Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS ADJUVANT THERAPY AFTER DEFINITIVE LOCAL THERAPY IN PATIENTS WITH HIGH-RISK LOCA... | |||||||||||||
Medical condition: Locally advanced squamous cell carcinoma of the head and neck (SCCHN) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) PL (Completed) FR (Completed) BE (Completed) PT (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000907-34 | Sponsor Protocol Number: H-200-001 | Start Date*: 2021-11-11 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Hookipa Biotech GmbH | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase I/II Study of TheraT® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: ES (Ongoing) FR (Ongoing) NL (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
